Sanofi Raises 2026 Revenue Target After Strong Mid‑Year Results

Sanofi published its semi‑annual financial report for the six months ended 30 June 2026, showing revenue of €11.6 billion, up 16 % at actual exchange rates and about 18 % on a constant‑currency basis. Adjusted earnings per share rose 31 % to €2.09.

The French biopharma also announced that its full‑year revenue growth goal has been lifted to roughly 10 % in 2026, from a previously modest low‑single‑digit target, after a quarter boosted by new medicines and strong sales of the blockbuster drug Dupixent. However, net profit fell sharply, with a loss of €343 million, driven by impairments on the recently terminated Amlitelimab research program for atopic dermatitis and higher profit‑sharing payments to partner Regeneron.

The report is available on Sanofi’s investor‑relations website and has been filed with the French market regulator AMF.